| First Author | Delbridge AR | Year | 2016 |
| Journal | Nat Rev Cancer | Volume | 16 |
| Issue | 2 | Pages | 99-109 |
| PubMed ID | 26822577 | Mgi Jnum | J:230649 |
| Mgi Id | MGI:5763502 | Doi | 10.1038/nrc.2015.17 |
| Citation | Delbridge AR, et al. (2016) Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies. Nat Rev Cancer 16(2):99-109 |
| abstractText | The 'hallmarks of cancer' are generally accepted as a set of genetic and epigenetic alterations that a normal cell must accrue to transform into a fully malignant cancer. It follows that therapies designed to counter these alterations might be effective as anti-cancer strategies. Over the past 30 years, research on the BCL-2-regulated apoptotic pathway has led to the development of small-molecule compounds, known as 'BH3-mimetics', that bind to pro-survival BCL-2 proteins to directly activate apoptosis of malignant cells. This Timeline article focuses on the discovery and study of BCL-2, the wider BCL-2 protein family and, specifically, its roles in cancer development and therapy. |
